ASAM president also medical director for drug company

I missed this a while back. Turns out that ASAM's president works for a buprenorphine manufacturer. Stuart Gitlow, M.D., is the president of the American Society of Addiction Medicine (ASAM) and also medical director — as a consultant — for Orexo, which makes Zubsolv, a newly approved buprenorphine-naloxone medication (see ADAW, July 15). The first public … Continue reading ASAM president also medical director for drug company

NAATP launches counteroffensive to medication push

This is very welcome news: Frustrated that medication-assisted treatment is coming across as the addiction field’s standard of care simply because drug company studies are dominating the research landscape, a group of some of the most prominent leaders in treatment administration is vowing to fight back. These leaders have enlisted the help of another heavy … Continue reading NAATP launches counteroffensive to medication push